Annexon, Inc.
ANNXDrugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Aug 13, 2026
16dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
How ANNX's past catalysts played out
Vonaprument
Geographic Atrophy
Tanruprubart
Guillain-Barre Syndrome
ANX005
Warm Autoimmune Hemolytic Anemia (wAIHA)
ANX007
Geographic Atrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Vonaprument | Phase 3 | Geographic Atrophy | - | - |
Tanruprubart | Phase 3 | Guillain-Barre Syndrome | - | - |
ANX005 | Phase 3 | Warm Autoimmune Hemolytic Anemia (wAIHA) | - | - |
ANX007 | Phase 2 | Geographic Atrophy | - | - |
Geographic Atrophy
2 drugs in this indication
Guillain-Barre Syndrome
1 drug in this indication
Warm Autoimmune Hemolytic Anemia (wAIHA)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Annexon, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Annexon, Inc.'s (ANNX) pipeline across Phase 3, Phase 2. Its lead program is Vonaprument (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Annexon, Inc.'s next FDA catalyst?→
Annexon, Inc.'s (ANNX) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ANNX biotech catalysts?→
Add ANNX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Annexon, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.